首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1668104

促卵泡激素市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按應用（不孕症治療、輔助生殖應用、其他）、按地區和競爭進行細分，2020-2030 年預測

Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application (Infertility Treatment, Assisted Reproductive Application, Others), By Region and Competition, 2020-2030F

出版日期: 2025年02月28日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球促卵泡激素市場價值為 18.6 億美元，預計到 2030 年將達到 22.1 億美元，預測期內複合年成長率為 5.84%。幾十年來，全球促卵泡激素 (FSH) 市場一直是醫療保健產業的重要參與者。 FSH 是一種在人類生殖中發揮重要作用的重要激素，是生育療法和激素替代療法的基本組成部分。隨著世界人口老化、不孕率上升以及人們對荷爾蒙相關疾病的認知不斷提高，FSH 市場經歷了顯著的成長和創新。促卵泡激素由腦下垂體前葉產生，是男性和女性生殖系統的關鍵調節因子。在女性中，FSH 會刺激卵泡的生長並引發排卵。在男性中，它會刺激睪丸產生精子。 FSH 水平失調會導致各種生殖健康問題，包括不孕症、月經不規則和荷爾蒙失衡。即時診斷（POC）檢測設備透過實現快速現場診斷徹底改變了醫療保健。在 FSH 市場，POC 設備使醫療保健提供者能夠立即獲得 FSH 測試結果，從而減少患者的等待時間並促進更快地做出治療決策。這對生育診所和生殖健康中心尤其有益。

市場概況
預測期	2026-2030
2024 年市場規模	18.6 億美元
2030 年市場規模	22.1 億美元
2025-2030 年複合年成長率	5.84%
成長最快的領域	不孕不育治療
最大的市場	北美洲

全球人口正在老化，越來越多的女性因為延後生育而尋求生育治療。這種人口趨勢導致對基於 FSH 的提高生育能力的療法的需求激增。隨著醫療保健資訊傳播的進步，人們對生育問題和荷爾蒙相關疾病的認知不斷提高，促使更多人尋求醫療協助，從而推動 FSH 市場的成長。生物技術和製藥領域的創新促進了更有效的 FSH 產品和療法的開發，從而提供了更好的效果並減少了副作用。許多國家的政府已採取措施支持輔助生殖技術和荷爾蒙替代療法。其中包括補貼治療、減少監管障礙和資助該領域的研究。

主要市場促進因素

不孕症盛行率的上升推動了全球促卵泡激素市場的發展

主要市場挑戰

生育治療費用高昂

主要市場趨勢

技術進步

Global Follicle Stimulating Hormone Market was valued at USD 1.86 Billion in 2024 and is expected to reach USD 2.21 Billion by 2030 with a CAGR of 5.84% during the forecast period. The global Follicle Stimulating Hormone (FSH) market has been a critical player in the healthcare industry for decades. FSH is a vital hormone that plays a significant role in human reproduction, making it a fundamental component of fertility treatments and hormone replacement therapy. As the world's population continues to age, infertility rates rise, and awareness about hormone-related disorders increases, the FSH market has witnessed significant growth and innovation. Follicle Stimulating Hormone, produced by the anterior pituitary gland, is a key regulator of the reproductive system in both men and women. In females, FSH stimulates the growth of ovarian follicles and triggers ovulation. In males, it stimulates the testes to produce sperm. Dysregulation of FSH levels can lead to various reproductive health issues, including infertility, irregular menstrual cycles, and hormone imbalances. Point-of-Care (POC) Testing devices have revolutionized healthcare by enabling rapid and on-site diagnostics. In the FSH market, POC devices have made it possible for healthcare providers to obtain immediate FSH test results, reducing patient wait times and facilitating faster treatment decisions. This is particularly beneficial for fertility clinics and reproductive health centers.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.86 Billion
Market Size 2030	USD 2.21 Billion
CAGR 2025-2030	5.84%
Fastest Growing Segment	Infertility Treatment
Largest Market	North America

The global population is aging, with an increasing number of women seeking fertility treatments as they delay parenthood. This demographic trend has led to a surge in demand for FSH-based therapies to enhance fertility. Increasing awareness about fertility issues and hormone-related disorders, driven by advancements in healthcare information dissemination, has encouraged more people to seek medical assistance, thereby driving FSH market growth. Innovations in the field of biotechnology and pharmaceuticals have led to the development of more effective FSH products and therapies, offering improved results and fewer side effects. Governments in many countries have taken steps to support assisted reproductive technologies and hormone replacement therapies. This includes subsidizing treatments, reducing regulatory barriers, and funding research in the field.

Key Market Drivers

Increasing Prevalence of Infertility is Driving the Global Follicle Stimulating Hormone Market

Infertility has become a growing concern worldwide, affecting millions of couples who dream of starting a family. In recent years, the prevalence of infertility has been on the rise, contributing to the expansion of the global Follicle Stimulating Hormone (FSH) market. As per the World Health Organization's data updated in April 2023, approximately 1 in 6 adults globally are affected by infertility. FSH, a crucial hormone for reproductive health, has gained prominence as a key player in fertility treatments. Infertility is a medical condition defined by the inability to conceive after a year of regular, unprotected sexual intercourse. It can result from various factors, including hormonal imbalances, age-related declines in fertility, structural issues, and lifestyle factors. Changing societal trends, including delayed marriages and career-focused lifestyles, have led many couples to postpone starting a family until later in life. Unfortunately, female fertility declines with age, making conception more challenging. Environmental toxins, pollutants, and the exposure to endocrine-disrupting chemicals have been linked to fertility issues. These factors can disrupt hormonal balance, including FSH levels, crucial for healthy reproductive function. The modern lifestyle, characterized by high stress levels, sedentary habits, and poor dietary choices, can negatively impact fertility. Stress hormones can interfere with reproductive hormones, including FSH. According to the

Key Market Challenges

High Cost of Fertility Treatments

One of the major challenges facing the Global Follicle Stimulating Hormone (FSH) Market is the high cost of fertility treatments, which often limits accessibility for a significant portion of the population. While FSH is essential for assisted reproductive technologies (ART) like in vitro fertilization (IVF), the overall cost of these procedures can be prohibitively expensive, particularly in low- and middle-income countries. The cost of FSH injections, along with the additional expenses associated with IVF cycles, such as diagnostic tests, consultations, and hospital stays, creates financial barriers for many individuals seeking fertility treatments. Multiple rounds of IVF may be required for success, further escalating costs. Despite the growing availability of fertility insurance in some regions, many patients still struggle with the affordability of these therapies. This economic challenge hinders market growth, as the high cost limits the number of people who can access and afford treatment. To overcome this barrier, there is a need for more affordable treatment options, government subsidies, and broader insurance coverage to make fertility treatments more accessible globally.

Key Market Trends

Technological Advancements

The field of medicine and healthcare is continuously evolving, with technological advancements playing a pivotal role in shaping the future of diagnostics and treatments. One such area experiencing significant growth is the global Follicle Stimulating Hormone (FSH) market. FSH is a critical hormone responsible for regulating the reproductive system in both men and women. The market for FSH has been witnessing remarkable growth, largely driven by advancements in technology and a growing demand for fertility treatments and diagnostic tools. One of the key technological advancements in the FSH market is the development of highly sensitive assays for FSH measurement. Traditional FSH assays were relatively less precise and had limitations in detecting low levels of the hormone. However, modern immunoassays and automated platforms have greatly improved the accuracy and sensitivity of FSH testing. This has made it easier for healthcare professionals to diagnose and monitor reproductive disorders with precision. Advances in microfluidics and biosensor technologies have led to the development of user-friendly home fertility testing kits. These kits allow individuals to monitor their FSH levels at home, providing valuable insights into their reproductive health. Such technology empowers individuals to take control of their fertility and seek medical intervention when necessary.

Key Market Players

Merck KgAa
Creative BioMart inc.
Midas Pharma GmbH
Genpharm Services
Livzon Pharmaceutical Group Inc
Shanghai Techwell Biopharmaceutical Co., Ltd
Medix Biochemica USA Inc.
Biogenix Inc.Pvt.Ltd.

Report Scope:

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type:

Recombinant FSH
Urinary FSH

Follicle Stimulating Hormone Market, By Application:

Infertility Treatment
Assisted Reproductive Application (ART)
Others

Follicle Stimulating Hormone Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicle Stimulating Hormone Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Recombinant FSH, Urinary FSH)
- 5.2.2. By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Follicle Stimulating Hormone Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Follicle Stimulating Hormone Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Follicle Stimulating Hormone Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Follicle Stimulating Hormone Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Follicle Stimulating Hormone Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Follicle Stimulating Hormone Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. United Kingdom Follicle Stimulating Hormone Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. Italy Follicle Stimulating Hormone Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. France Follicle Stimulating Hormone Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Follicle Stimulating Hormone Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia-Pacific Follicle Stimulating Hormone Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Follicle Stimulating Hormone Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Follicle Stimulating Hormone Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Follicle Stimulating Hormone Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Follicle Stimulating Hormone Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Follicle Stimulating Hormone Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. South America Follicle Stimulating Hormone Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Follicle Stimulating Hormone Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Follicle Stimulating Hormone Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Follicle Stimulating Hormone Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. Middle East and Africa Follicle Stimulating Hormone Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Follicle Stimulating Hormone Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Follicle Stimulating Hormone Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Follicle Stimulating Hormone Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Midas Pharma GmbH
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Creative BioMart inc.
14.3. Genpharm Services
14.4. Merck KgAa
14.5. Livzon Pharmaceutical Group Inc
14.6. Shanghai Techwell Biopharmaceutical Co., Ltd
14.7. Medix Biochemica USA Inc.
14.8. Biogenix Inc.Pvt.Ltd.